Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
-
- Caicun Zhou
- Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, China
-
- Suresh S. Ramalingam
- Winship Cancer Institute of Emory University, Atlanta, Georgia
-
- Tae Min Kim
- Seoul National University Hospital, Seoul, South Korea
-
- Sang-We Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
-
- James Chih-Hsin Yang
- National Taiwan University Cancer Center, Taipei, Taiwan
-
- Gregory J. Riely
- Memorial Sloan Kettering Cancer Center, New York, New York
-
- Tarek Mekhail
- AdventHealth Orlando, Orlando, Florida
-
- Danny Nguyen
- Pacific Shores Medical Group, Long Beach, California
-
- Maria R. Garcia Campelo
- Complejo Hospitalario Universitario A Coruña Hospital Teresa Herrera-Materno Infantil, A Coruña, Spain
-
- Enriqueta Felip
- Vall d’Hebron University Hospital, Barcelona, Spain
-
- Sylvie Vincent
- Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts
-
- Shu Jin
- Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts
-
- Celina Griffin
- Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts
-
- Veronica Bunn
- Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts
-
- Jianchang Lin
- Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts
-
- Huamao M. Lin
- Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts
-
- Minal Mehta
- Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts
-
- Pasi A. Jänne
- Dana-Farber Cancer Institute, Boston, Massachusetts
書誌事項
- タイトル別名
-
- A Phase 1/2 Open-label Nonrandomized Clinical Trial
収録刊行物
-
- JAMA Oncology
-
JAMA Oncology 7 (12), e214761-, 2021-12-16
American Medical Association (AMA)